Skip to main content

HomeResearchDalargin

CategoryRecovery
SafetyLow Risk
StatusResearch Only

Dalargin

Leu-enkephalin-Arg · YGGFLR · dalarginum

CategoryRecovery
Half-life
Routesubcutaneous, intravenous
RiskLow Risk
ProvidersNone listed

About Dalargin

Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.

A synthetic hexapeptide opioid analog with a leucine-enkephalin core extended by a C-terminal arginine. Developed in the Soviet Union for gastroprotective and analgesic applications. Studied for GI mucosal protection and pain modulation with peripheral preference.

Research Areas

gastroprotectionGI repairanti-ulcerpain modulation

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Safety Notes

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

Pregnant Or Nursing

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Find Dalargin

Coverage expanding

No verified providers currently list Dalargin. Get notified when one does, or explore providers carrying similar peptides in the Recovery category.

Frequently Asked Questions — Dalargin

A synthetic hexapeptide opioid analog with a leucine-enkephalin core extended by a C-terminal arginine. Developed in the Soviet Union for gastroprotective and analgesic applications.

gastroprotection, GI repair, anti-ulcer, pain modulation.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.